Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 14, 2026, 1:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 106 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: insulin regular IV infusion Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Autonomic Nervous System and the Metabolic Syndrome

NCT00580957
View directory record Official record
Conditions
Obesity
Interventions
Blocked, Intact
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 60 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 4, 2016 · Synced Sep 14, 2026, 1:48 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Role of Glucagon In Glucose Control in Cystic Fibrosis Related Diabetes

NCT02398383
View directory record Official record
Conditions
Cystic Fibrosis, Cystic Fibrosis Related Diabetes
Interventions
Oral Glucose Tolerance Test, Mixed Meal Tolerance Test, Hypoglycemic Clamp
Other
Lead sponsor
Yale University
Other
Eligibility
12 Years to 45 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 25, 2020 · Synced Sep 14, 2026, 1:48 PM EDT
Completed Not applicable Interventional Results available

The Effect of Tight Glycemic Control on Surgical Site Infection Rates in Patients Undergoing Open Heart Surgery

NCT01831154
View directory record Official record
Conditions
Diabetes, Hyperglycemia, Surgical Site Infection
Interventions
Tight Glycemic, Conventional Glycemic, Standard Glycemic
Drug
Lead sponsor
James A. Haley Veterans Administration Hospital
Federal
Eligibility
21 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 23, 2017 · Synced Sep 14, 2026, 1:48 PM EDT
Completed Phase 2 Interventional Results available

Rituximab in New Onset Type 1 Diabetes

NCT00279305
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Anti-CD20 (rituximab), Placebo Comparator
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
8 Years to 45 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
13
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 5, 2020 · Synced Sep 14, 2026, 1:48 PM EDT
Withdrawn Phase 3 Interventional

Intensive Glycemic Control on Infectious Morbidity In Patients With Acute Leukemia

NCT00943709
View directory record Official record
Conditions
Hyperglycemia, Leukemia
Interventions
insulin glargine recombinant, therapeutic insulin
Biological · Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 29, 2013 · Synced Sep 14, 2026, 1:48 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Liver Glycogen and Hypoglycemia in Humans

NCT03241706
View directory record Official record
Conditions
Hypoglycemia; Iatrogenic
Interventions
Low Fructose, Saline, Somatostatin, Insulin, Glucagon, Dextrose solution, High Fructose
Drug
Lead sponsor
Jason Winnick
Other
Eligibility
21 Years to 40 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2028
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced Sep 14, 2026, 1:48 PM EDT
Completed Phase 3 Interventional Results available

Intensive Insulin Therapy in Patients Undergoing Coronary Artery Bypass Surgery

NCT01361594
View directory record Official record
Conditions
Diabetes
Interventions
Regular insulin (intensive treatment), Regular Insulin (conventional treatment)
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 30, 2014 · Synced Sep 14, 2026, 1:48 PM EDT
Withdrawn Phase 1 Interventional

Autonomic Blockade and Endogenous Glucose Production

NCT03028571
View directory record Official record
Conditions
Insulin Resistance
Interventions
Trimethaphan, Saline
Drug · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Sep 14, 2026, 1:48 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Assessment of Mechanisms of Improved Wound Healing

NCT00673309
View directory record Official record
Conditions
Burns
Interventions
Stable Isotope Infusion study, Insulin High Dose, oxandrolone, Propranolol, Growth Hormone, Insulin Low Dose, IGF-1/IGFBP-3, Itraconazole, Growth Hormone and Propranolol, Oxandrolone and Propranolol, Placebo or Control
Procedure · Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
Up to 90 Years
Enrollment
644 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2013
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 2, 2023 · Synced Sep 14, 2026, 1:48 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Role of Alpha-to-beta Cell Communication to Adapt Insulin Secretion to Insulin Resistance.

NCT07224334
View directory record Official record
Conditions
Diabetes (DM)
Interventions
Exendin-9 is a 30 amino acid peptide that is an established competitive antagonist of the GLP-1 receptor. Subjects will receive exendin-9 by intravenous infusion at a rate of 600 pmol/kg/min, Dexamethasone
Drug
Lead sponsor
David D'Alessio, M.D.
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 14, 2026, 1:48 PM EDT
Terminated Not applicable Interventional

Early Administration of Long-acting Insulin Treatment of Diabetic Ketoacidosis in Pediatric Type 1 Diabetes

NCT02548494
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetic Ketoacidosis
Interventions
Glargine, IV insulin, Electrolyte Correction, Correction of Fluid Loss
Drug · Other
Lead sponsor
Chattanooga-Hamilton County Hospital Authority
Other
Eligibility
1 Year to 21 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 22, 2020 · Synced Sep 14, 2026, 1:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Molar Potency Study of HM12460A in Healthy Subjects

NCT03330314
View directory record Official record
Conditions
Healthy Volunteers
Interventions
HM12460A
Biological
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 60 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Sep 14, 2026, 1:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Type 2 Diabetes and the Brain in Adolescents

NCT03461510
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Obesity, Pediatric Obesity, Insulin Resistance, Dysglycemia, Hyperglycemia
Interventions
Hyperglycemic clamp, Hyperinsulinemic Euglycemic clamp
Procedure
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
12 Years to 18 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 8, 2019 · Synced Sep 14, 2026, 1:48 PM EDT
Active, not recruiting Phase 2 Interventional

Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults, Adolescents and Children on Top of Insulin Therapy (FABULINUS)

NCT06111586
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Frexalimab, Placebo, Insulin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
6 Years to 35 Years
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
14
States / cities
San Francisco, California • Aurora, Colorado • Gainesville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 14, 2026, 1:48 PM EDT
Active, not recruiting Phase 2 Interventional

A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants

NCT03253263
View directory record Official record
Conditions
Bronchopulmonary Dysplasia, Chronic Lung Disease of Prematurity, Intraventricular Hemorrhage, Retinopathy of Prematurity (ROP)
Interventions
OHB-607
Drug
Lead sponsor
OHB Neonatology Ltd.
Industry
Eligibility
0 Hours to 24 Hours
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
24
States / cities
Little Rock, Arkansas • California City, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 14, 2026, 1:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Intrapartum Glycemic Control With Insulin Infusion Versus Rotating Fluids

NCT03912363
View directory record Official record
Conditions
Type II Diabetes Mellitus, Gestational Diabetes Mellitus
Interventions
Rotating fluids protocol, Insulin infusion protocol
Other
Lead sponsor
Geisinger Clinic
Other
Eligibility
14 Years to 50 Years · Female only
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
2
States / cities
Danville, Pennsylvania • Wilkes-Barre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Sep 14, 2026, 1:48 PM EDT
Completed Phase 4 Interventional Results available

Effect of Ethanol Intoxication on the Anti-Hypoglycemic Action of Glucagon

NCT02516150
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Ethanol, Glucagon
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
21 Years to 80 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 30, 2017 · Synced Sep 14, 2026, 1:48 PM EDT
Completed Phase 2 Interventional Results available

New Onset of Type 1 Diabetes Mycophenolate Mofetil-Daclizumab Clinical Trial

NCT00100178
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Mycophenolate mofeteil (MMF), Daclizumab (DZB), Placebo control for Mycophenolate mofeteil (MMF), Placebo control for Daclizumab (DZB)
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
8 Years to 45 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
10
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 4, 2020 · Synced Sep 14, 2026, 1:48 PM EDT
Completed Phase 2 Interventional Results available

IGF-1/IGFBP3 Prevention of Retinopathy of Prematurity

NCT01096784
View directory record Official record
Conditions
Retinopathy of Prematurity (ROP)
Interventions
rhIGF-I/rhIGFBP-3
Drug
Lead sponsor
Shire
Industry
Eligibility
Up to 1 Day
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
8
States / cities
Mobile, Alabama • Irvine, California • Augusta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Sep 14, 2026, 1:48 PM EDT
Completed Not applicable Interventional Results available

Role of Glucagon-Like Peptide-1 in Postprandial Hypoglycemia

NCT01162499
View directory record Official record
Conditions
Postprandial Hypoglycemia
Interventions
Exendin-(9-39), Vehicle
Drug · Other
Lead sponsor
Diva De Leon
Other
Eligibility
6 Months to 18 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 22, 2017 · Synced Sep 14, 2026, 1:48 PM EDT
Terminated Phase 4 Interventional Results available

Early Basal Insulin Administration in Adult Diabetic Ketoacidosis Management

NCT04567225
View directory record Official record
Conditions
Diabetic Ketoacidosis, Type 1 Diabetes, Type 2 Diabetes
Interventions
Early Glargine, Late Glargine, IV insulin infusion, IV fluid and electrolytes replacement
Drug · Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 20, 2022 · Synced Sep 14, 2026, 1:48 PM EDT
Completed Phase 4 Interventional Results available

Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery

NCT02556918
View directory record Official record
Conditions
Hyperglycemia
Interventions
Sitagliptin, Placebo, Regular Human Insulin, Insulin glargine, Supplemental insulin (Insulin lispro), Supplemental insulin (Insulin aspart)
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 22, 2019 · Synced Sep 14, 2026, 1:48 PM EDT
Suspended Phase 4 Interventional

Feasible Insulin Algorithm for Glycemic Control in Patients With Acute Coronary Syndrome

NCT01151176
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Regular Insulin
Drug
Lead sponsor
Universidade Positivo
Other
Eligibility
18 Years to 80 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 18, 2012 · Synced Sep 14, 2026, 1:48 PM EDT
Completed Not applicable Interventional Results available

Comparative Trial Between 3 Types of Insulin Infusion Protocols

NCT00582309
View directory record Official record
Conditions
Hyperglycemia
Interventions
Glucommander-Guided Intravenous Insulin Infusion, Standard Intravenous Insulin Infusion, Simple Calculated Intravenous Insulin Infusion
Procedure
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 80 Years
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
3
States / cities
Chicago Heights, Illinois • Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jun 22, 2015 · Synced Sep 14, 2026, 1:48 PM EDT